A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
| Autor: | Helmut G. Schrott, Thomas W. Littlejohn, Richard McLain, Robert H. Knopp, Harold E. Bays, Peter H. Jones, Donald M. Black, Anita Gmerek Fereshetian |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Apolipoprotein B Atorvastatin 030204 cardiovascular system & hematology Placebo Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine Pharmacology (medical) 030212 general & internal medicine Adverse effect Cause of death Pharmacology biology business.industry Cholesterol Dose-ranging study Endocrinology chemistry biology.protein lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Lipoprotein medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology and Therapeutics. 3:119-123 |
| ISSN: | 1940-4034 1074-2484 |
| DOI: | 10.1177/107424849800300204 |
| Popis: | Background: Coronary heart disease (CHD) is the number one cause of death in Western societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer ides (TG) increase the risk for CHD. 3-Hydroxy-3-methylglutaryl conenzyme A (HMG- CoA) reductase inhibitors effectively reduce plasma cholesterol levels in patients with hypercholesterolemia. This study assesses the safety and dose-related effects of atorvastatin calcium on lipoprotein fractions in patients with LDL cholesterol levels between 160 mg/dL (4.1 mM) and 250 mg/dL (6.5 mM) or less and TG levels of 400 mg/dL (4.5 mM) or less. Methods and Results: Sixty-five patients were enrolled in a 6-week, randomized, placebo- controlled, parallel-group study. Patients received placebo or atorvastatin 10, 20, 40, 60, or 80 mg once daily. Adjusted mean decreases in LDL cholesterol for patients receiving ator vastatin 10, 20, 40, 60, and 80 mg were 37%, 42%, 50%, 52%, and 59%, respectively, com pared with a mean increase of 0.3% for patients receiving placebo; the differences between each of the atorvastatin dose groups and placebo were statistically significant ( P = .0001). Total cholesterol, triglycerides, and apolipoprotein B were significantly reduced in atorva statin groups ( P = .0001). Adverse events were similar in the placebo and atorvastatin treat ment groups. No patient had a serious adverse event or withdrew because of an adverse event during this study. Conclusions: Atorvastatin effectively lowered plasma LDL cholesterol, triglycerides, and apoB levels in a dose-related manner. Atorvastatin was well tolerated in hyperlipidemic patients over a 6-week period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|